MNC (JVs and subsidiaries) | |
Industry | Pharmaceutical |
Founded | 1983 |
Headquarters | Hinjwadi, Pune, India |
Key people
|
Satish Mehta CEO |
Products | tablets, capsules, softgels, injectables, Lyophilized sterile parenterals, Onco products |
₹1,500+ crore (US$220;Million) | |
Number of employees
|
9000+ |
Website | www.emcure.co.in |
Satish Mehta
Emcure Pharmaceuticals headquartered at Pune in West India is an Indian pharmaceutical company. The company's products include tablets, capsules (both softgel capsules and hard-gel capsules), and injectables.
USA - The company has a manufacturing facility and R&D center at East Brunswick, New Jersey, USA.
Emcure is planning to raise money through an initial public offering for some time now In 2014, Blackstone sold its stake in Emcure to Bain Capital
There have been cases of recalls announced by Pharma majors like Pfizer & Teva after having manufactured their products with their partner Emcure. In 2010, Pfizer had to recall three batches of an anti-bacterial product from the US market due to presence of Penicillium Chrysogenum & E coli in some samples. Teva recalled several batches of two products due to white tablets showing discoloration in 2011.
Emcure voices its concerns on HIV/AIDS through its "Let's fight AIDS together" initiative and supplies Antiretroviral drugs to Africa, Asia Pacific and CIS. As a part of its corporate social responsibility it supports 'Taal', a pharmacy for HIV/AIDS patients run by HIV/AIDS patients.
Emcure has license agreements with Bristol-Myers Squibb for Atazanavir and Gilead Sciences for Tenofovir as part of their Global Access Programs.
Roche has signed a deal with Emcure for manufacturing its blockbuster anticancer drugs Herceptin and Mabthera in India. Under this programme the cancer drugs shall be made available to the developing world at an affordable 'cut-price' version. The monthly doses priced at around $300000 are expected to be slashed significantly for wider access to cancer therapy.